Genostics

12/02/2025

Available in Australia through Genostics

maintrac® Quality:

Fast and reproducible results, performed in a DIN EN ISO 15189 certified laboratory, accredited by DAkkS (ILAC approved), in Bayreuth, Germany.

18/04/2024

30/05/2023

In the International maintrac Online Forum on May 9, 2023, Prof. Dr. Pachmann reported on how the number of circulating epithelial tumor cells changes during...

16/05/2023

May is National Cancer Research Month 👩‍🔬👨‍🔬

Cancer affects many people. Therefore, cancer research is of particular importance to further improve diagnostics and therapy options. The maintrac research team is tirelessly researching new diagnostic possibilities in the field of circulating tumor cells.

You can find our latest publications about that topic on our website www.maintrac.de/en

27/09/2022

The physician notices poor cooperation during adjuvant hormone therapy.

www.maintrac.com

In breast cancer patients, fluctuating cell counts of circulating tumor cells may occur during anti-hormonal hormone therapy. These can be detected with the control instrument maintrac®.

If the physician asks, some patients admit to having forgotten to take the pill from time to time. It is precisely in these women that adjuvant hormone therapy has the greatest success. The missed doses can be identified by the number of circulating tumor cells. When the drug is then taken again, the cell count quickly drops again.

If the drug schedule is followed, the number of circulating tumor cells decreases continuously. However, the tumor cells are not completely killed, but enter a dormant state.

However, if regular checks with maintrac® show that the cell counts are increasing, the therapy is ineffective. The physician should quickly change the therapy to prevent a relapse.

06/06/2022

PD-L1 is overexpressed on tumorspheres cultured from cancer stem cells in breast cancer patients

maintrac at AACR 2022



maintrac is a blood test that detects circulating Tumor cells in the blood sample of a cancer patient.�
Almost every tumor releases cells into the bloodstream. maintrac identifies and counts there circulating tumor cells in a bloodsample.

Monitoring the therapy by repeatingly testing for circulating tumor cells can help to intervene more quickly if the therapy does not achieve the desired result thereby even to prevent metastases.

maintrac is the most sensitive method to identify circulating tumor cells. It can find down to a minimum of 10.000 life circulating epithelial tumor cells in the whole blood circulation.

One of the main advantages of maintrac is that maintrac keeps the cells alive. A second one is that maintrac needs no fixation, isolation and enrichment to find the cells. The circulating epithelial tumor cells are identified with a semiautomated microscopic image evaluation.

maintrac can identify cells from almost every solid cancer like breastcancer (mammacarcinoma), lungcancer (bronchialcarcinoma), skincancer (melanoma), ovariancancer (ovariancarcinoma), prostatecancer (prostatecarcinoma), stomachcancer (stomachcarcinoma) in neoadjuvant, adjuvant and metastatic situation, in endocrine treatment as well as in longterm surveillance.

www.maintrac.com

04/04/2019

This is what it looks like inside the laser-scanning cytometer... At first it was like lifting the bonnet of a car and feeling a bit overwhelmed at all the k***s and tubes, but now I can lift the lid with a spanner and screwdriver in my hands and troubleshoot the laser settings with the machine running...

02/04/2019

Hello from the Maintrac lab, Germany. These samples are ready for biomarker testing. Biomarkers are proteins on the outside of a cell that can be used as a target for certain treatments.

Here we are testing to see if a patient's Circulating Tumour Cells actually have the biomarkers specifically targeted by the intended cancer treatment.